Drug Name | Active Ingred | Mfr | Indication | Approval Date | AHFS Class | NDA Chem Type* | Appl No |
---|---|---|---|---|---|---|---|
Abilify Mycite® | aripiprazole with ingestible event marker (IEM) | Otsuka | schizophrenia, bipolar disorder, major depressive disorder | 2017/11/13 | 28:16.08.04 - Atypical Antipsychotics | 4 | 207202 |
Admelog® | insulin lispro | Sanofi Aventis | diabetes mellitus | 2017/12/11 | 68:20.08 - Insulins | 5S | 209196 |
Adzenys® ER | amphetamine | Neos | attention deficit hyperactivity disorder (ADHD) | 2017/09/15 | 28:20.04 - Amphetamines | 3S | 204325 |
AirDuoTM Respiclick® | fluticasone propionate; salmeterol | Teva | asthma | 2017/01/27 | 68:04 - Adrenals; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 4S | 208799 |
Aliqopa® | copanlisib | Bayer | relapsed follicular lymphoma (FL) | 2017/09/14 | 10:00 - Antineoplastic Agents | 1P/O | 209936 |
Altafluor Benox® | fluorescein; benoxinate | Altaire | tonometry, gonioscopy | 2017/12/14 | 36:58 - Ocular Disorders; 52:16 - Local Anesthetics | 4P | 208582 |
Alunbrig® | brigatinib | Ariad | anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) | 2017/04/28 | 10:00 - Antineoplastic Agents | 1P | 208772 |
ArmonAirTM Respiclick® | fluticasone propionate | Teva | asthma | 2017/01/27 | 68:04 - Adrenals | 5S | 208798 |
Arymo ER® | morphine sulfate | Egalet | severe pain requiring daily, around-the-clock, long-term opioid treatment | 2017/01/09 | 28:08.08 - Opiate Agonists | 5S | 208603 |
Ascor® | ascorbic acid | McGuff | scurvy | 2017/10/02 | 88:12 - Vitamin C | 7S | 209112 |
AHFS Class | Change Date | Change Description |
---|---|---|
26:00 - Cellular and Gene Therapy | 2017/09/08 | Rename class from Cellular Therapy |
26:04 - Cellular Therapy | 2017/09/08 | New subclass |
26:12 - Gene Therapy | 2017/09/08 | New subclass |
28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors | 2017/10/16 | New subclass |
68:16.08 - Antiestrogens | 2017/09/20 | Revived old class that was retired in 2007 |
68:18 - Gonadotropins and Antigonadotropins | 2017/09/15 | Rename class from Gonadotropins |
68:18.04 - Antigonadotropins | 2017/09/15 | New subclass |
68:18.08 - Gonadotropins | 2017/09/15 | New subclass |
68:24 - Parathyroid and Antiparathyroid Agents | 2017/08/10 | Rename class from Parathyroid |
68:24.04 - Antiparathyroid Agents | 2017/08/10 | New subclass |
Drug Name(s) | Active Ingred | Change Date | Old AHFS Class | New AHFS Class |
---|---|---|---|---|
Aclovate® | alclometasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
Ala-Cort®, Anucort-HC®, Anusert-HC®, Anusol-HC®, Cetacort®, Cortizone®, Dermacort®, Lanacort®, Proctocort®, Sarnol-HC®, Texacort®, Westcort® | hydrocortisone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
Alphatrex®, Betatrex®, Beta-Val®, Diprolene®, Luxiq®, Maxivate® | betamethasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
Antagon® | ganirelix | 2017/09/15 | 92:40 - Gonadotropin-releasing Hormone Antagonists | 68:18.04 - Antigonadotropins |
Arimidex® | anastrozole | 2017/09/20 | 10:00 - Antineoplastic Agents | 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents |
Aristocort®, Flutex®, Kenalog®, Triacet® | triamcinolone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
Aromsin® | exemestane | 2017/09/20 | 10:00 - Antineoplastic Agents | 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents |
Austedo® | deutetrabenazine | 2017/10/16 | 28:92 - CNS Agents, Misc | 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors |
Capex®, Derma-Smoothe/FS®, Lidex®, Lidex-E®, Synalar®, Synemol® | fluocinolone/fluocinonide | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
Cetrotide® | cetrorelix | 2017/09/15 | 92:40 - Gonadotropin-releasing Hormone Antagonists | 68:18.04 - Antigonadotropins |